← Back to patent-cliff list
Paltusotine
Tier C — Watch / tradePaltusotine
Crinetics Pharmaceuticals Inc
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SSTR2
Brand：PALSONIFY
Indications (approved)：Acromegaly
Regional status
US
Approved
2025-09-25
EU
Approved
2026-04-23
China
Discontinued
2021-12-17
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Paltusotine?
Approved indications include: Acromegaly.
When does the Paltusotine patent expire?
No public expiry year is available for Paltusotine yet; this page updates once verified.
How do I get a quote for Paltusotine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01